GlassScriptPhysician profile
Ariel D Graham
NPI 1710414719
$6,317.36
in general payments reported to CMS, 2019-2025
41 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $986 · 2022: $1,128 · 2023: $1,336 · 2024: $1,702 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,169.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $526.64 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.86 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $418.97 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $413.79 | 2022-2025 | |
| Amgen INC. | $352.93 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $256.80 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $238.64 | 2021-2023 | Ajovy |
| Axsome Therapeutics, INC. | $220.17 | 2023-2025 | Auvelity, Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.82 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $216.65 | 2021-2025 | |
| Novo Nordisk INC | $207.62 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $156.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.13 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $123.89 | 2022-2025 | Trelegy Ellipta, Arexvy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.